SEC Filing Summary: AdventRX Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by AdventRX Pharmaceuticals, Inc. on November 3, 2004, reporting events that occurred on November 2, 2004. The company is a Delaware corporation headquartered in San Diego, California. The filing addresses developments regarding the Company's CoFactor Phase II clinical trial and current plans for regulatory filings.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the announcement of specific developments concerning the CoFactor Phase II trial and updated regulatory filing plans. No financial performance changes versus prior periods are detailed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the CoFactor Phase II trial developments and regulatory plans. The full details of these matters are contained in the press release dated November 2, 2004, which is included as Exhibit 99.1. No specific risks, contingencies, or unusual items are described within the body of this 8-K text.
Key Facts for Investor Verification
- Verify the specific outcomes of the CoFactor Phase II trial by reviewing the attached press release (Exhibit 99.1).
- Confirm the details of the Company's current regulatory filing plans as announced on November 2, 2004.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.